West Pharma beats Q2, raises FY 2025 guidance; declares Q4 dividend

WEST PHARMACEUTICAL SERVICES INC

2025-Q2 EPS reported $3.05 vs consensus $1.52 ▲ beat (+100.0%)

Net sales $766.5M (+9.2% YoY); diluted EPS $1.82 vs $1.51; adjusted EPS $1.84 vs $1.52.
FY 2025 net sales guidance raised to $3.04-3.06B (from $2.945-2.975B); adjusted EPS raised to $6.65-6.85.
Proprietary Products sales $619.8M (+10.7%); HVP components up 11.3% driven by GLP-1 elastomer growth.
Board declares Q4 dividend $0.22/share, payable Nov 19, record Nov 12.
First-half 2025 free cash flow $160M (from $92.4M); repurchased 552,593 shares for $134M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.